- $14.39m
- -$3.15m
Annual balance sheet for BioVie, fiscal year end - June 30th, USD millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 4.51 | 18.6 | 33.9 | 23.8 | 17.5 |
| Net Total Receivables | — | — | — | — | 2.1 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 4.61 | 18.8 | 34 | 24 | 20.7 |
| Net Property, Plant And Equipment | — | 0.118 | 0.081 | 0.407 | 0.34 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Other Long Term Assets | |||||
| Total Assets | 6.05 | 20.1 | 35.1 | 25.2 | 21.6 |
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 0.996 | 4.17 | 14.5 | 9.35 | 2.27 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 0.996 | 16.4 | 19.8 | 9.7 | 2.55 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Other Equity | |||||
| Total Equity | 5.05 | 3.67 | 15.3 | 15.5 | 19 |
| Total Liabilities & Shareholders' Equity | 6.05 | 20.1 | 35.1 | 25.2 | 21.6 |
| Total Common Shares Outstanding |